The obesity market size is projected to witness growth
from 2024 to 2034 due to the rising prevalence of obesity. This
expansion is expected to be further influenced by the extensive
pipeline of emerging drugs, characterized by lower safety risks and
improved profiles, throughout the study period.
LAS VEGAS, June 18, 2024 /PRNewswire/ -- DelveInsight's
Obesity Market Insights report includes a comprehensive
understanding of current treatment practices, obesity emerging
drugs, market share of individual therapies, and current and
forecasted market size from 2020 to 2034, segmented into 7MM
[the United States, the EU4
(Germany, France, Italy, and Spain) and the United Kingdom, and Japan].
Key Takeaways from the Obesity Market Report
- As per DelveInsight analysis, the obesity market size in the US
was USD 1.2 billion in
2022.
- In 2023, the total prevalent population of obesity
in the United States was ~114
million cases, which as per DelveInsight's estimates, is
expected to increase by 2034.
- Leading obesity companies such as Novo Nordisk A/S,
Pfizer, Boehringer Ingelheim, Eli Lilly and Company, Rhythm
Pharmaceuticals, Inc., ACADIA Pharmaceuticals Inc., Harmony
Biosciences, LLC, Soleno Therapeutics, Inc., and others are
developing novel obesity drugs that can be available in the obesity
market in the upcoming years.
- The obesity therapies in the pipeline include Oral
semaglutide, Danuglipron (PF-06882961), Survodutide (BI 456906),
Liraglutide, Cagrilintide, Orforglipron, Setmelanotide, Carbetocin,
Pitolisant, DCCR, and others.
- In November 2023, the FDA
approved Eli Lilly and Company's ZEPBOUND (tirzepatide) injection,
for the treatment of obesity that activates both glucose-dependent
insulinotropic polypeptide (GIP) and glucagon-like peptide-1
(GLP-1) hormone receptors.
- In December 2023, Pfizer
announced topline data from the Phase IIb clinical trial
(NCT04707313) investigating its oral glucagon-like peptide-1
receptor agonist (GLP-1RA) candidate, danuglipron (PF-06882961), in
adults with obesity and without Type 2 diabetes. The study met its
primary endpoint demonstrating statistically significant change in
body weight from baseline.
Discover which therapies are expected to grab major
obesity market share @ Obesity Market Report
Obesity Overview
Obesity is acknowledged as a chronic condition or
noncommunicable ailment, characterized by a complex, multifaceted
set of factors. It predominantly involves excessive body fat, along
with being overweight, which can have metabolic implications beyond
just physical size. Individuals grappling with obesity often face
social and psychological stigma, leading to discrimination in
various aspects of life, including personal relationships and
employment, contributing to low self-esteem and depression.
Childhood obesity can lead to similar health complications as adult
obesity, sometimes even with an earlier onset.
The development of obesity is influenced by a combination of
genetic predisposition and environmental factors. Certain severe
and early-onset forms of obesity stem from mutations in genes
related to the leptin-melanocortin axis, such as LEPR, POMC, MC4R,
NTRK2, and SIM1. One of the most noticeable indicators of obesity
is the accumulation of excess adipose tissue, typically assessed
through anthropometric measurements. Common symptoms include
stretch marks, high blood pressure, and a body mass index (BMI)
exceeding 30 kg/m². Some symptoms can exacerbate, increasing the
risk of developing various diseases and disorders.
Obesity Epidemiology Segmentation
According to DelveInsight's analyst, the diagnosed prevalent
cases of obesity are on the rise, and as per the estimates,
the United States accounted for
~61% and ~66% of cases for adults (<19 years) and
children (5–19 years), respectively, in 2023.
The obesity market report proffers epidemiological analysis
for the study period 2020–2034 in the 7MM segmented into:
- Total Prevalent Cases of Obesity
- Total Obesity Patients Seeking Help
- Total Treated Cases of Obesity
Obesity Treatment Market
Weight reduction via nutritious eating, upping physical
activity, and adopting lifestyle modifications are frequently
employed treatments for obesity. Certain individuals might find
weight management programs helpful for shedding excess weight or
preventing its return. However, some obese individuals struggle to
shed adequate weight to improve their well-being or to sustain
their weight loss. In such cases, alternative therapies like
weight-loss medications, devices, or bariatric surgery could be
contemplated.
Alternative methods for obesity treatment include cutting-edge
techniques. For instance, hydrogels are ingestible capsules
containing tiny particles that soak up stomach water, triggering a
sense of satiety. Vagal nerve blockade employs an implanted device
beneath the skin of the abdomen to send electrical signals to the
vagus nerve, signaling fullness to the brain. Gastric aspirate, a
surgical intervention, involves placing a tube through the abdomen
to remove a portion of stomach contents post-meals regularly. These
varied approaches highlight the continuous progress in combating
obesity.
FDA-approved treatments for obesity comprise CONTRAVE
(bupropion-naltrexone), a blend of drugs that diminish appetite
and cravings; SAXENDA (liraglutide), an injectable that
curbs appetite and influences how quickly the stomach empties;
Alli and XENICAL (orlistat), which obstruct pancreatic
lipase to help manage obesity; QSYMIA
(phentermine-topiramate), a prescription medication that
suppresses appetite and fosters weight loss; IMCIVREE
(setmelanotide), sanctioned for genetic-based obesity; and
WEGOVY (semaglutide), an injectable drug that supports
weight loss in adults with obesity or overweight when paired with a
reduced-calorie diet and increased physical activity.
Learn more about the FDA-approved obesity drugs @ Drugs
for Obesity Treatment
Obesity Pipeline Therapies and Key Companies
Some of the drugs in the obesity pipeline include Oral
semaglutide (Novo Nordisk), Danuglipron (PF-06882961) (Pfizer),
Survodutide (BI 456906) (Boehringer Ingelheim), and others.
RYBELSUS, known as oral semaglutide, has received
approval in the US, EU, and Japan
as a complement to diet and exercise for enhancing glycemic control
in adults with type II diabetes. It operates as an oral GLP-1 RA,
mimicking the function of the natural hormone GLP-1. Additionally,
the company is progressing in its development of this medication
for treating obesity. Currently undergoing Phase III testing
(NCT05564117; OASIS 4), the drug's safety and effectiveness are
being assessed in individuals who are overweight or obese.
Activation of the glucagon-like peptide-1 receptor (GLP-1R)
leads to decreased blood sugar levels and weight loss, offering a
promising approach for managing Type II diabetes and obesity.
Pfizer has introduced danuglipron (PF-06882961), an
oral GLP-1R agonist. In June 2023,
Pfizer declared its intention to advance danuglipron for further
clinical evaluation as a potential treatment for obesity in adults.
Subsequently, in December 2023,
Pfizer released initial findings from a Phase IIb clinical trial
assessing danuglipron in obese adults without T2D. The trial
successfully demonstrated a significant reduction in body weight
compared to the baseline, marking a positive outcome for the
study's primary objective.
The other late-stage therapies for obesity treatment in
development include:
- Liraglutide: Novo Nordisk A/S
- Cagrilintide: Novo Nordisk A/S
- Orforglipron: Eli Lilly and Company
- Setmelanotide: Rhythm Pharmaceuticals, Inc.
- Carbetocin: ACADIA Pharmaceuticals Inc.
- Pitolisant: Harmony Biosciences, LLC
- DCCR: Soleno Therapeutics, Inc.
The anticipated launch of these emerging therapies for obesity
are poised to transform the market landscape in the coming years.
As these cutting-edge therapies continue to mature and gain
regulatory approval, they are expected to reshape the obesity
market landscape, offering new standards of care and unlocking
opportunities for medical innovation and economic growth.
Discover more about drugs for obesity in development @
Obesity Clinical Trials
Obesity Market Dynamics
The dynamics of the obesity market are expected to change in the
coming years. Pharmaceutical companies are increasing investment
in drug research and development, with emerging mobile
technologies offering unprecedented possibilities for understanding
and intervening in obesity; key players like Novo Nordisk and
Eli Lilly and Company are addressing unmet needs in the obesity
market, while governmental and nongovernmental bodies work
to raise awareness, expanding the market as patients seek
treatment.
As many potential therapies are being investigated for the
treatment of obesity, it is safe to predict that the treatment
space will significantly impact the obesity market during the
forecast period. Moreover, the anticipated introduction of
emerging therapies with improved efficacy and a further
improvement in the diagnosis rate are expected to drive the
growth of the obesity market in the 7MM.
However several factors may impede the growth of the obesity
market. There is no consensus on the best obesity treatment,
as conventional medical interventions often fail in the long run
for the great majority of obese individuals. Additionally, there is
a huge disparity in terms of disease staging systems used in
the treatment landscape of obesity, highlighting the need to form a
consensus on when or if to use different staging systems.
The comorbidities associated with obesity require additional
medications and treatments, complicating obesity management, which
leads to increased costs and reduced patient adherence.
Furthermore, obesity impacts the patient's quality of life,
resulting in high absenteeism, unemployment, and sometimes
psychosocial issues, imposing a threat to the market as the
focus of patients shifts from obesity to its associated
comorbidities such as diabetes, depression, and cardiovascular
changes.
Moreover, obesity treatment poses a significant economic
burden and disrupts patients' overall well-being and QOL.
Furthermore, the obesity market growth may be offset by
failures and discontinuation of emerging therapies,
unaffordable pricing, market access and reimbursement
issues, and a shortage of healthcare specialists. In
addition, the undiagnosed, unreported cases and the
unawareness about the disease may also impact the
obesity market growth.
Report
Metrics
|
Details
|
Study Period
|
2020–2034
|
Coverage
|
7MM [The United States,
the EU-4 (Germany, France, Italy, and Spain), the United Kingdom,
and Japan]
|
Obesity Market Size in
the US in 2022
|
USD 1.2
Billion
|
Key Obesity
Companies
|
Novo Nordisk A/S,
Pfizer, Boehringer Ingelheim, Eli Lilly and Company, Rhythm
Pharmaceuticals, Inc., ACADIA Pharmaceuticals Inc., Harmony
Biosciences, LLC, Soleno Therapeutics, Inc., and others
|
Key Obesity Therapies
|
Oral semaglutide,
Danuglipron (PF-06882961), Survodutide (BI 456906), Liraglutide,
Cagrilintide, Orforglipron, Setmelanotide, Carbetocin, Pitolisant,
DCCR, and others
|
Scope of the Obesity Market Report
- Therapeutic Assessment: Obesity current marketed
and emerging therapies
- Obesity Market Dynamics: Attribute Analysis
of Emerging Obesity Drugs
- Competitive Intelligence Analysis: SWOT analysis
and Market entry strategies
- Unmet Needs, KOL's Views, Analyst's Views, Obesity Market
Access and Reimbursement
To know more about obesity treatment options, visit @ New
Treatment for Obesity
Table of Contents
1.
|
Obesity Market
Key Insights
|
2.
|
Obesity Market
Report Introduction
|
3.
|
Obesity Market Overview
at a Glance
|
4.
|
Obesity Market
Executive Summary
|
5.
|
Disease Background and
Overview
|
6.
|
Obesity
Treatment and Management
|
7.
|
Obesity
Epidemiology and Patient
Population
|
8.
|
Patient
Journey
|
9.
|
Obesity Marketed
Drugs
|
10.
|
Obesity
Emerging Drugs
|
11.
|
7 Major
Obesity Market Analysis
|
12.
|
Obesity
Market Outlook
|
13.
|
Potential of Current
and Emerging Therapies
|
14.
|
KOL Views
|
15.
|
Obesity
Market Drivers
|
16.
|
Obesity
Market Barriers
|
17.
|
Unmet Needs
|
18.
|
SWOT
Analysis
|
19.
|
Appendix
|
20.
|
DelveInsight
Capabilities
|
21.
|
Disclaimer
|
22.
|
About
DelveInsight
|
Related Reports
Obesity Epidemiology Forecast
Obesity Epidemiology Forecast – 2032 report
delivers an in-depth understanding of the disease, historical and
forecasted epidemiology as well as the obesity epidemiology
trends.
Obesity Pipeline
Obesity Pipeline Insight
– 2024 report provides comprehensive insights
about the pipeline landscape, including clinical and non-clinical
stage products, and the key obesity companies, including
180 Life Sciences, 9 meters, Aardvark Therapeutics, Adocia,
Agentix, AgeX Therapeutics, Altimmune, Amgen, Antag Therapeutics,
Aphaia Pharma, Aptorum Group, AstraZeneca, Bukwang Pharmaceutical,
Caliway Biopharmaceutics Co Ltd, Can Fite Biopharma, Carmot
Therapeutics, Inc., Cellivery Therapeutics Inc, CinFina Pharma,
Clayton Biotech, Click Therapeutics, Corbus Pharma, DiscoveryBiomed
Inc, Dong-A ST, Dongkook Pharmaceuticals, Eccogene, Elevian, Eli
Lilly and Company, Empros Pharma, Enterin Inc., EraCal Therapeutics
AG, ERX Pharmaceuticals, ERX Pharmaceuticals, Eternygen GmbH,
Eurofarma, Gannex Pharma, Glaceum, Gmax Biopharm, GPER G-1
Development Group, LLC, Gubra Therapeutics, Hanmi Pharmaceutical,
Hanmi Pharmaceuticals, Innovent Biologics, Jenrin Discovery,
Jiangsu Hansoh Pharmaceutical, Kallyope, Kintai Therapeutics, Kriya
Therapeutics, LG Life Sciences, Lipidio Pharmaceuticals,
MakScientific, Nano Precision Medical, NeonMind Biosciences,
Novartis, Novo Nordisk, NuSirt Biopharma, Otsuka Pharmaceutical
Factory Inc, Pfizer, Raziel Therapeutics, Reata Pharmaceuticals,
Regeneron Pharmaceuticals, Reviva Pharmaceuticals, Rivus
Pharmaceuticals, Shionogi, SHIONOGI & Co., Ltd., Sigrid
Therapeutics, SJT Molecular Research SL, Structure Therapeutics,
Sun Pharmaceutical Industries, Techfields Pharma, Terns
Pharmaceuticals, Tonix Pharmaceuticals, UGISense AG, Versanis Bio,
Viking Therapeutics, YSOPIA Bioscience, Yuhan, Zealand Pharma,
among others.
Hypothalamic Obesity Market
Hypothalamic Obesity Market Insights,
Epidemiology, and Market Forecast – 2032 report
delivers an in-depth understanding of the disease, historical and
forecasted epidemiology, market share of the individual therapies,
and key hypothalamic obesity companies, including
Altimmune, Saniona, YSOPIA Bioscience, Innovent Biologics,
among others.
Hypothalamic Obesity Pipeline
Hypothalamic Obesity Pipeline Insight
– 2023 report provides comprehensive insights
about the pipeline landscape, including clinical and non-clinical
stage products and the key hypothalamic obesity companies,
including Altimmune, Saniona, YSOPIA Bioscience, Innovent
Biologics, among others.
About DelveInsight
DelveInsight is a leading Business Consultant and Market
Research firm focused exclusively on life sciences. It supports
pharma companies by providing comprehensive end-to-end solutions to
improve their performance. Get hassle-free access to all the
healthcare and pharma market research reports through our
subscription-based platform PharmDelve.
Contact Us
Shruti
Thakur
info@delveinsight.com
+14699457679
Logo:
https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg
View original
content:https://www.prnewswire.co.uk/news-releases/obesity-market-to-observe-impressive-growth-by-2034-assesses-delveinsight--key-companies---novo-nordisk-as-pfizer-boehringer-ingelheim-eli-lilly-and-company-rhythm-pharmaceuticals-harmony-biosciences-302175060.html